Table of Contents
- A Word From the Editor
- Introduction
- Prognostic Markers in Patients with NSCLC: ERCC1 and RRM1 as Markers of Improved Prognosis in NSCLC
- Oligonucleotide-based Gene Expression Signatures of Improved Survival in Resected NSCLC Patients
- Serum Proteomic Profiles as Prognostic Marker of Improved Prognosis in NSCLC
- Markers That Predict for Therapeutic Efficacy
- ERCCI as a Predictor for Platinum Resistance in Advanced NSCLC
- RRMI as a Predictor of Gemcitabine(Drug information on gemcitabine) Efficacy
- BRCA1 as a Predictor of Chemotherapy Efficacy
- Predictors of Improved Response or Survival with EGFR Tyrosine Kinase Inhibitors
- Oligonucleotide-based Gene Expression Profiles as Predictors of Response in NSCLC Patients
- Individualizing Treatment for Advanced Stage NSCLC Using ERCC1 and RRM1
- Conclusions
- References
CONTINUING MEDICAL EDUCATION
Activity Release Date: December 15, 2008
Activity Expiration Date: December 15, 2009
About the Activity
This activity is based on a brief article developed as part of the E-Update Series and posted on the Web. It was developed from an identified educational need for information about practical management issues in the practice of medical, surgical, and radiation oncology. This activity has been developed and approved under the direction of CME LLC.
Activity Learning Objectives
After reading this article, participants should be able to:
1. Demonstrate an understanding of the appropriate role of surgery in the metastatic setting:
• Role of tackling the unexplored mediastinum in patients who have undergone resection
• Role of surgery after chemoradiation in stage IIIA NSCLC
2. Apply into practice the role of radiation therapy post resection in the treatment of N2 NSCLC:
•PORT = Post-Operative Radiation Therapy
•STARBOARD = Sidestepping Trans-Thoracic Adjuvant Radiation Therapy Because One is Averse to Radiation Damage
3. Analyze the efficacy of molecular profiling for cytotoxics and targeted agents
4. Appraise the use of induction therapy versus adjuvant therapy
5. Demonstrate an understanding of the possible role consolidation versus observation after Initial Therapy
Target Audience
This activity targets physicians in the fields of oncology and hematology.
Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of CME LLC and The Oncology Group. CME LLC is accredited by the ACCME to provide continuing medical education for physicians.
Continuing Education Credit
AMA PRA Category 1 Credit™
CME LLC designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™ . Physicians should only claim credit commensurate with the extent of their participation in the activity.
Compliance Statement
This activity is an independent educational activity under the direction of CME LLC. The activity was planned and implemented in accordance with the Essential Areas and policies of the ACCME, the Ethical Opinions/Guidelines of the AMA, the FDA, the OIG, and the PhRMA Code on Interactions with Healthcare Professionals, thus assuring the highest degree of independence, fair balance, scientific rigor, and objectivity.
However, CME LLC, the Grantor, and CMPMedica shall in no way be liable for the currency of information or for any errors, omissions, or inaccuracies in the activity. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Activity participants are encouraged to refer to primary references or full prescribing information resources. The opinions and recommendations presented herein are those of the author(s) and do not necessarily reflect the views of the provider or producer.
Financial Disclosures
Dr. Langer has received grant and research support from Bristol-Myers Squibb, ImClone, Pfizer, Lilly, Schering-Plough Research Institute, Sanofi-Aventis, Amgen, Cell Therapeutics Inc, OrthoBiotech, Celgene, Vertex, Genentech, OSI, AstraZeneca, Active Biotech, Medimmune (absorbed by AZ 2008); has served as scientific advisor for Bristol-Myers Squibb, ImClone, Sanofi-Aventis, Pfizer, IntraBiotics, GlaxoSmithKline, Pharmacyclics, Amgen, AstraZeneca, Novartis, Genentech, Savient, Bayer, Onyx, Abraxis, and Abbott; and has served on the speaker’s bureau for Bristol-Myers Squibb, Sanofi-Aventis, Lilly, OrthoBiotech, Genentech, and OSI. Dr. Simon has no financial relationships to disclose.
Copyright
Copyright owned by CME LLC. Copyright 2008, all rights reserved.
Contact Information
We would like to hear your comments regarding this or other activities provided by CME LLC. In addition, suggestions for future activities are welcome. Contact us at:
Director of Continuing Education
CME LLC
Harborside Financial Center
Plaza 3, Suite #806
Jersey City, NJ 07311
The goal of this activity is to clarify challenging treatment issues of HER2+ breast cancer including incorporation of predictive and prognostic biomarker tests and evidence-based data into practice when determining individualized strategies that improve patient survival and quality of life.
